Conversion from Mycophenolate Mofetil to Mizoribine in the Early Stages of BK Polyomavirus Infection Could Improve Kidney Allograft Prognosis: a Single-center Study from China

Overview

Journal BMC Nephrol

Publisher Biomed Central

Specialty Nephrology

Date 2021 Oct 3

PMID 34600511

Authors

Ping Li

Dongrui Cheng

Jiqiu Wen

Xuefeng Ni

Kenan Xie

Xue Li

Jinsong Chen

Affiliations

Soon will be listed here.

Abstract

Background: Some studies have suggested mizoribine (MZR) could inhibit the replication of BK polyomavirus (BKPyV). The purpose of this study was to explore whether conversion from mycophenolate mofetil (MMF) to MZR in the early stages of BKPyV infection can improve kidney allograft prognosis.

Methods: Twenty-one kidney transplant recipients with BKPyV viruria/viremia and ten with BK polyomavirus-associated allograft nephropathy (BKPyVAN) received MZR conversion therapy were retrospectively identified. The clearance rate of urine and blood BKPyV DNA, change of serum creatinine (SCr), uric acid (UA), hemoglobin (HB), white blood cell (WBC), lymphocyte ratio, platelet (PLT), routine urinalysis, panel reactive antibody (PRA), and gastrointestinal disorders during follow-up of the 2 groups were evaluated and compared.

Results: After MZR conversion therapy, the clearance rate of urine and blood viral load in BKPyV viruria/viremia group were 85.7 and 100 %, while that in BKPyVAN were 40 and 87.5 %, respectively. Stable SCr were observed in all cases of BKPyV viruria/viremia group, while that of BKPyVAN was only 40 % (P < 0.001) and one even progressed to end-stage renal disease. The results of routine urinalysis in the two groups showed no significant changes before and after MZR conversion therapy. However, in BKPyV viruria/viremia group, four cases developed acute rejection and one had positive PRA-II but no donor specific antibody, requiring conversion back to MMF. Hyperuricemia was the common adverse effect of MZR.

Conclusions: Conversion from MMF to MZR could help clear BKPyV infection. As compared to BKPyVAN, patients who underwent initiation of MZR conversion therapy in the early stages of BKPyV infection maintained stable allograft function. Prospective studies with larger sample size are needed to ascertain this preliminary finding.

References

Kuramoto T, Daikoku T, Yoshida Y, Takemoto M, Oshima K, Eizuru Y . Novel anticytomegalovirus activity of immunosuppressant mizoribine and its synergism with ganciclovir. J Pharmacol Exp Ther. 2010; 333(3):816-21. DOI: 10.1124/jpet.109.160630. View

Haas M, Loupy A, Lefaucheur C, Roufosse C, Glotz D, Seron D . The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell-mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials. Am J Transplant. 2017; 18(2):293-307. PMC: 5817248. DOI: 10.1111/ajt.14625. View

Vigil D, Konstantinov N, Barry M, Harford A, Servilla K, Kim Y . BK nephropathy in the native kidneys of patients with organ transplants: Clinical spectrum of BK infection. World J Transplant. 2016; 6(3):472-504. PMC: 5036119. DOI: 10.5500/wjt.v6.i3.472. View

Yuan X, Chen C, Zheng Y, Wang C . Conversion From Mycophenolates to Mizoribine Is Associated With Lower BK Virus Load in Kidney Transplant Recipients: A Prospective Study. Transplant Proc. 2018; 50(10):3356-3360. DOI: 10.1016/j.transproceed.2018.01.059. View

Funahashi Y, Hattori R, Kinukawa T, Kimura H, Nishiyama Y, Gotoh M . Conversion from mycophenolate mofetil to mizoribine for patients with positive polyomavirus type BK in urine. Transplant Proc. 2008; 40(7):2268-70. DOI: 10.1016/j.transproceed.2008.07.069. View

Sugiyama K, Satoh H, Saito K, Takahashi K, Saito N, Hirano T . Immunosuppressive efficacy of mycophenolate mofetil when compared with azathioprine and mizoribine against peripheral lymphocytes from renal transplant recipients. Transpl Int. 2005; 18(5):590-5. DOI: 10.1111/j.1432-2277.2005.00093.x. View

Yokota S . Mizoribine: mode of action and effects in clinical use. Pediatr Int. 2002; 44(2):196-8. DOI: 10.1046/j.1328-8067.2002.01536.x. View

Shi Y, Liu H, Chen X, Shen Z . Comparison of Mizoribine and Mycophenolate Mofetil With a Tacrolimus-Based Immunosuppressive Regimen in Living-Donor Kidney Transplantation Recipients: A Retrospective Study in China. Transplant Proc. 2017; 49(1):26-31. DOI: 10.1016/j.transproceed.2016.10.018. View

Hirsch H, Randhawa P . BK polyomavirus in solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant. 2019; 33(9):e13528. DOI: 10.1111/ctr.13528. View

10.

Kuypers D . Management of polyomavirus-associated nephropathy in renal transplant recipients. Nat Rev Nephrol. 2012; 8(7):390-402. DOI: 10.1038/nrneph.2012.64. View

11.

Hirsch H, Randhawa P . BK polyomavirus in solid organ transplantation. Am J Transplant. 2013; 13 Suppl 4:179-88. DOI: 10.1111/ajt.12110. View

12.

Oshiro Y, Nakagawa K, Hoshinaga K, Aikawa A, Shishido S, Yoshida K . A Japanese multicenter study of high-dose mizoribine combined with cyclosporine, basiliximab, and corticosteroid in renal transplantation (the fourth report). Transplant Proc. 2013; 45(4):1476-80. DOI: 10.1016/j.transproceed.2013.03.016. View

13.

Ushigome H, Uchida K, Nishimura K, Akioka K, Fukuda Y, Yuzawa K . Efficacy and Safety of High-Dose Mizoribine Combined With Cyclosporine, Basiliximab, and Corticosteroids in Renal Transplantation: A Japanese Multicenter Study. Transplant Proc. 2016; 48(3):794-8. DOI: 10.1016/j.transproceed.2015.12.117. View

14.

Li P, Cheng D, Wen J, Ni X, Li X, Xie K . The immunophenotyping of different stages of BK virus allograft nephropathy. Ren Fail. 2019; 41(1):855-861. PMC: 6758702. DOI: 10.1080/0886022X.2019.1617168. View

15.

Yanagida K, Baba C, Baba M . Inhibition of bovine viral diarrhea virus (BVDV) by mizoribine: synergistic effect of combination with interferon-alpha. Antiviral Res. 2004; 64(3):195-201. DOI: 10.1016/j.antiviral.2004.09.001. View

16.

Ramos E, Drachenberg C, Wali R, Hirsch H . The decade of polyomavirus BK-associated nephropathy: state of affairs. Transplantation. 2009; 87(5):621-30. DOI: 10.1097/TP.0b013e318197c17d. View

17.

Xing S, Yang J, Zhang X, Zhou P . Comparative efficacy and safety of mizoribine with mycophenolate mofetil for Asian renal transplantation--a meta-analysis. Clin Biochem. 2014; 47(7-8):663-9. DOI: 10.1016/j.clinbiochem.2014.01.014. View

18.

Tsuzuki K . Role of mizoribine in renal transplantation. Pediatr Int. 2002; 44(2):224-31. DOI: 10.1046/j.1328-8067.2001.01531.x. View

19.

Li S, Gong M, Sun Y, Shao J, Zhang Y, Chang H . In Vitro and in Vivo Antiviral Activity of Mizoribine Against Foot-And-Mouth Disease Virus. Molecules. 2019; 24(9). PMC: 6539406. DOI: 10.3390/molecules24091723. View

20.

Ishikawa H . Mizoribine and mycophenolate mofetil. Curr Med Chem. 1999; 6(7):575-97. View